Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
The private group taps DualityBio for an EGFR x HER3 ADC.
